ZBH FY2025 Q4 SOFTENING

Zimmer Biomet Holdings, Inc. 실적 발표

Feb 10, 2026 · 08:30 ET David DiMartinoSukhya PatiaYvonne Tornos

Buzzberg 분석

Guiding 2026 organic growth of 1% to 3%, down from 2025's 3.9%.

Zimmer Biomet reported a strong Q4 2025 beat on the top line with 5.4% growth, but offered a cautious 2026 revenue outlook of only 1-3% growth, citing the significant disruption expected from the multi-year restructuring of its US sales channel. The company is prioritizing debt reduction and share buybacks over M&A during this transition. Q4 2025 reported organic constant currency revenue growth of 5.4%, with US growth at 5.7% and international at 5%, reported EPS of $2.42.

Buzzberg 분석 Guiding 2026 organic growth of 1% to 3%, down from 2025's 3.9%. Zimmer Biomet reported a strong Q4 2025 beat on the top line with 5.4% growth, but offered a cautious 2026 revenue outlook of only 1-3% growth, citing the significant disruption expected from the multi-year restructuring of its US sales channel. The company is prioritizing debt reduction and share buybacks over M&A during this transition. Q4 2025 reported organic constant currency revenue growth of 5.4%, with US growth at 5.7% and international at 5%, reported EPS of $2.42. 전체 분석 보기분석 접기

2026 revenue guidance of 1-3% growth, reflecting a deliberate step-down from the +5% exit rate due to the US Salesforce transformation and international go-to-market changes.
Company generating strong free cash flow ($1.2B in 2025, 11% growth), with 2026 expected to continue with 8-10% FCF growth.
The US commercial organization is being transitioned to a fully dedicated and specialized sales model, a process expected to be complete by end of 2027.

Revenue $2.2438B reported

EPS $2.42 reported

Gross margin 64.68% reported

Op margin 12.83% reported

이번 분기에 달라진 점

Guidance

Guiding 2026 organic growth of 1% to 3%, down from 2025's 3.9%.

Guidance · revenue to 2%

Sales Strategy

U.S. sales force transition to be completed by end of 2027.

Q4 2025 reported organic constant currency revenue growth of 5.4%, with US growth at 5.7% and international at 5%, reported EPS of $2.42.

Capital Allocation

Company to prioritize buybacks over M&A in 2026.

2026 revenue guidance of 1-3% growth, reflecting a deliberate step-down from the +5% exit rate due to the US Salesforce transformation and international go-to-market changes.

Innovation

mBoss robotic system to launch in 2027, showcased at AAOS.

Company generating strong free cash flow ($1.2B in 2025, 11% growth), with 2026 expected to continue with 8-10% FCF growth.

AI, 자본지출 및 수요 분석

플랫폼 및 수익화

Management discussed the mBoss semi and fully autonomous AI-driven orthopedic robotic system, acquired via the Monogram acquisition. They plan to launch it in 2027 and showcased it at AAOS, emphasizing its potential to change the standard of care.

수요

수주 및 전환

Management's tone is cautious, guiding to low-single-digit growth in 2026, explicitly citing short-term disruption from a massive US sales force restructuring which outweighs a strong Q4 exit rate.

톤 · Confident

Management expressed confidence in strategic initiatives, new product momentum, and long-term growth, while acknowledging short-term disruption from the sales force transition.

공급망 알파

Zimmer Biomet is executing a multi-year overhaul of its entire US sales channel, moving from a largely non-dedicated (1099) and non-specialized model to a fully dedicated and specialized one. The company states current productivity is roughly half of direct competitors, and that the transition could take through 2027 to complete.

SYK ENGGY SMMNY

“The evolution of the U.S. Salesforce represents the final core initiative in a transformation. And while it might create some short-term disruption across pockets of an organization, it is by far the most crucial step in order to convert Z…”

Yvonne Tornos

Zimmer Biomet is prioritizing shareholder returns over M&A in 2026, pausing its diversification strategy after the integrations of Paragon 28 and Monogram, and receiving board approval to buy back up to $1.5 billion in stock.

“I wouldn't say it's a change. I would say that it's a pause. ... It's not a time to add more complexity. This is not a time to run more projects.”

Yvonne Tornos

The Paragon 28 (foot & ankle) and Monogram (robotics) acquisitions are still being fully integrated, with plans for eight new product launches in 2026. The company remains committed to double-digit growth for Paragon 28 after starting to consolidate it.

“So we're very excited about the business. Again, two quarters behind. I just left the sales meeting in San Diego a couple of weeks ago. I'll tell you, Ryan, that with eight new products being launched in 2026, with virtually the same legac…”

Yvonne Tornos

향후 가이던스

SofteningGuidance · revenue to 2%

향후 가이던스
지표	기간	범위	중간값	상태
EPS	FY2026	$8.30–$8.45	$8.38	GUIDED
Free cash flow	FY2026	8%–10%	9%	GUIDED
Revenue	FY2026	1%–3%	2%	GUIDED

기업 영향 분석

SYK

-13.5%

발표 이후

$361.06→$312.26

ENGGY

—

발표 이후

—→—

SMMNY

-5.7%

발표 이후

$24.12→$22.75

공급망공급망 알파

Zimmer Biomet is executing a multi-year overhaul of its entire US sales channel, moving from a largely non-dedicated (1099) and non-specialized model to a fully dedicated and specialized one. The company states current productivity is roughly half of direct competitors, and that the transition could take through 2027 to complete. — This deliberate sales disruption in the US is a direct driver of the company's lowered 2026 guidance, signaling a potential near-term share shift in the large-joints market as competitors (Stryker, Enovis, Smith+Nephew) may capitalize on the disruption.

“The evolution of the U.S. Salesforce represents the final core initiative in a transformation. And while it might create some short-term disruption across pockets of an organization, it is by far the most crucial step in order to convert”

Yvonne Tornos